CNCE Concert Pharmaceuticals Inc

Price (delayed)

$3.31

Market cap

$106.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.37

Enterprise value

$30.36M

Highlights
CNCE's EPS is up by 23% year-on-year
The quick ratio has increased by 22% YoY and by 7% from the previous quarter
The company's equity fell by 26% YoY and by 13% QoQ
CNCE's net income is down by 2.9% since the previous quarter

Key stats

What are the main financial stats of CNCE
Market
Shares outstanding
32.17M
Market cap
$106.5M
Enterprise value
$30.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
14.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.84
Earnings
Revenue
$7.9M
EBIT
-$77.04M
EBITDA
-$75.15M
Free cash flow
-$72.11M
Per share
EPS
-$2.37
Free cash flow per share
-$2.13
Book value per share
$3.54
Revenue per share
$0.23
TBVPS
$4.13
Balance sheet
Total assets
$139.99M
Total liabilities
$25.95M
Debt
$14.79M
Equity
$114.04M
Working capital
$115.55M
Liquidity
Debt to equity
0.13
Current ratio
14.92
Quick ratio
14
Net debt/EBITDA
1.01
Margins
EBITDA margin
-951.3%
Gross margin
100%
Net margin
-974.2%
Operating margin
-987%
Efficiency
Return on assets
-49.3%
Return on equity
-59.5%
Return on invested capital
-73.8%
Return on capital employed
-58.5%
Return on sales
-975.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CNCE stock price

How has the Concert Pharmaceuticals stock price performed over time
Intraday
-1.19%
1 week
-4.34%
1 month
-20.24%
1 year
-63.55%
YTD
-73.81%
QTD
-21.56%

Financial performance

How have Concert Pharmaceuticals's revenue and profit performed over time
Revenue
$7.9M
Gross profit
$7.9M
Operating income
-$77.98M
Net income
-$76.96M
Gross margin
100%
Net margin
-974.2%
The net margin has surged by 99% year-on-year but it has declined by 3% since the previous quarter
The operating margin has soared by 99% YoY but it fell by 7% QoQ
The operating income is down by 7% from the previous quarter
CNCE's net income is down by 2.9% since the previous quarter

Growth

What is Concert Pharmaceuticals's growth rate over time

Valuation

What is Concert Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.93
P/S
14.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.84
CNCE's EPS is up by 23% year-on-year
CNCE's P/B is 61% below its 5-year quarterly average of 2.4 and 58% below its last 4 quarters average of 2.2
The company's equity fell by 26% YoY and by 13% QoQ
The P/S is 98% below the 5-year quarterly average of 647.8 and 64% below the last 4 quarters average of 39.8

Efficiency

How efficient is Concert Pharmaceuticals business performance
CNCE's return on sales has surged by 99% year-on-year but it is down by 3% since the previous quarter
The ROIC has contracted by 24% from the previous quarter and by 14% YoY
The ROE has contracted by 11% from the previous quarter
The ROA has contracted by 11% from the previous quarter and by 3.1% YoY

Dividends

What is CNCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CNCE.

Financial health

How did Concert Pharmaceuticals financials performed over time
CNCE's current ratio is up by 26% YoY and by 6% from the previous quarter
The total assets is down by 25% year-on-year and by 12% since the previous quarter
The debt is 87% smaller than the equity
CNCE's debt to equity is up by 30% year-on-year and by 18% since the previous quarter
The company's equity fell by 26% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.